Gastrointestinal Protein Loss in Rheumatoid Arthritis, Studied with51cr-Chromic Chloride and125i Albumin

Publisher Website
Google Scholar
Abstract
Patients with rheumatoid arthritis and healthy controls have been studied with respect to the gastrointestinal excretion during 7 days of 51Cr-activity after the intravenous administration of 51Cr-CrCl3 according to a method described by Rootwelt, 1966. Most of the subjects included were simultaneously studied with respect to albumin pools and catabolism by l23I-labelled albumin. 1. The control group had a mean cumulative 51Cr excretion during 7 days of 0.7±0.33 % of the dose. 2. The patients with rheumatoid arthritis had a mean 51Cr excretion of 1.7±1.0% of the dose, which is significantly higher than the mean control value. 3. The low normal chromium excretion makes it possible to assess even small elevations of the gastrointestinal protein loss. 4. The possibility that the small gastrointestinal protein loss could be a symptom of early amyloid vascular lesion in patients with long-standing rheumatoid arthritis is pointed out. 5. Intravenous injection of 51Cr-CrCl3 is a comparatively convenient method for the diagnosis and quantitation of gastrointestinal protein loss.

This publication has 14 references indexed in Scilit: